180 related articles for article (PubMed ID: 19179898)
21. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.
Edelman MJ; Schneider CP; Tsai CM; Kim HT; Quoix E; Luft AV; Kaleta R; Mukhopadhyay P; Trifan OC; Whitaker L; Reck M
J Clin Oncol; 2013 Jun; 31(16):1990-6. PubMed ID: 23589560
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
23. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
Cohen RB; Langer CJ; Simon GR; Eisenberg PD; Hainsworth JD; Madajewicz S; Cosgriff TM; Pierce K; Xu H; Liau K; Healey D
Cancer Chemother Pharmacol; 2007 Jun; 60(1):81-9. PubMed ID: 17031646
[TBL] [Abstract][Full Text] [Related]
24. Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Goto Y; Sekine I; Yamada K; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
J Thorac Oncol; 2008 Apr; 3(4):412-6. PubMed ID: 18379361
[TBL] [Abstract][Full Text] [Related]
25. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
26. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2.
Kosmidis PA; Syrigos K; Kalofonos HP; Dimopoulos MA; Skarlos D; Pavlidis N; Boukovinas I; Bafaloukos D; Pectasides D; Bacoyiannis C; Fountzilas G
Anticancer Res; 2012 Jan; 32(1):175-81. PubMed ID: 22213304
[TBL] [Abstract][Full Text] [Related]
27. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.
Jahnke K; Keilholz U; Lüftner D; Thiel E; Schmittel A
Anticancer Res; 2011 Jan; 31(1):317-23. PubMed ID: 21273617
[TBL] [Abstract][Full Text] [Related]
29. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
30. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
Tan EH; Tan DS; Li WY; Haaland B; Ang MK; Chau NM; Toh CK; Tan IB; Koh TS; Thng CH; Chowbay B; Hui KM; Lim WT; Ng QS
Lung Cancer; 2015 Jun; 88(3):289-96. PubMed ID: 25896396
[TBL] [Abstract][Full Text] [Related]
31. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
32. VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.
Shingyoji M; Ando S; Nishimura H; Nakajima T; Ishikawa A; Itakura M; Iizasa T; Kimura H
Anticancer Res; 2009 Jul; 29(7):2635-9. PubMed ID: 19596939
[TBL] [Abstract][Full Text] [Related]
33. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
35. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
36. [Circulating endothelial cells in the peripheral blood of advanced NSCLC patients].
Huang C; Li K; Wei XY; Niu RF; Sun Y; Wang JW; Zhu YZ; Xu LY; Liu XQ; Gao HJ; Zhou JM; Wang XW
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):780-3. PubMed ID: 17366796
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment Pokemon Level as a Predictor of Response to Cisplatin and Paclitaxel in Patients with Unresectable Non-Small Cell Lung Cancer.
Zhang QL; Xing XZ; Li FY; Xing YJ; Li J
Oncol Res Treat; 2015; 38(10):496-502. PubMed ID: 26451776
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Bidard FC; Mathiot C; Degeorges A; Etienne-Grimaldi MC; Delva R; Pivot X; Veyret C; Bergougnoux L; de Cremoux P; Milano G; Pierga JY
Ann Oncol; 2010 Sep; 21(9):1765-1771. PubMed ID: 20233745
[TBL] [Abstract][Full Text] [Related]
40. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
